StreetInsider.com News Articles

Form 8-K TScan Therapeutics, Inc. For: Jun 22

Mon, 22 Jun 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260622/26669812.html

Form 8-K TScan Therapeutics, Inc. For: Jun 22

Mon, 22 Jun 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260622/26669812.html

TScan reports early Phase 1 data showing chimerism gains with TSC-101

Mon, 22 Jun 2026 07:00:14 -0400

TScan Therapeutics (Nasdaq: TCRX) reported initial data from Cohort C of its ALLOHA Phase 1 study evaluating TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation.

Of 19 patients enrolled in Cohort C, 14 proceeded to transplant and received a first infusion of TSC-101. Eleven of those 14 patients achieved complete donor chimerism within approximately three weeks of their first infusion. Two of the remaining three patients showed improving chimerism. All five patients assessed after a second infusion showed complete donor chimerism.

The company reported a manufacturing success rate of approximately 90%, or 17 of 19 patients, using its commercial-ready

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Trans

Mon, 22 Jun 2026 07:00:00 -0400

11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101

TSC-101 continues to be well-tolerated

Company remains on track to enroll their first patient in the Phase 3 ALLOHA-2™ study of TSC-101 this month

Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., today, June 22, at 8:30 a.m. ET

WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Trans

Mon, 22 Jun 2026 07:00:00 -0400

11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101

TSC-101 continues to be well-tolerated

Company remains on track to enroll their first patient in the Phase 3 ALLOHA-2™ study of TSC-101 this month

Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., today, June 22, at 8:30 a.m. ET

WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the

Cellares and TScan partner to evaluate automated manufacturing for cancer therapy

Wed, 03 Jun 2026 09:19:50 -0400

Cellares and TScan Therapeutics Inc. (NASDAQ: TCRX) announced an agreement to evaluate automated manufacturing of TSC-101, TScan's lead T cell receptor-engineered T cell therapy candidate for treating acute myeloid leukemia and myelodysplastic syndromes.

The collaboration will assess Cellares' Cell Shuttle and Cell Q platforms for manufacturing TSC-101, which is designed to treat residual disease and prevent relapse in patients undergoing allogeneic hematopoietic cell transplantation. TScan expects to begin a pivotal trial for TSC-101 in the second quarter of 2026.

Under the agreement, Cellares will automate TSC-101 manufacturing and testing processes using its end-to-end manufacturing platform and automated quality control system. The closed-system

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Wed, 03 Jun 2026 09:19:00 -0400

Collaboration will apply Cellares' fully automated Cell Shuttle® and Cell Q™ platforms to TScan’s lead TCR-T therapy candidate TSC-101 as a potentially scalable and cost-efficient path to commercialization

SOUTH SAN FRANCISCO, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)-- Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced an agreement to evaluate automated clinical manufacturing of TSC-101, TScan's lead TCR-T therapy candidate for patients with acute myeloid leukemia

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Wed, 03 Jun 2026 09:19:00 -0400

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Wed, 03 Jun 2026 09:19:00 -0400

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Wed, 03 Jun 2026 09:19:00 -0400

Form 4 TScan Therapeutics, Inc. For: May 20 Filed by: 667, L.P.

Fri, 22 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260522/26541639.html

Form 4 TScan Therapeutics, Inc. For: May 20 Filed by: 667, L.P.

Fri, 22 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260522/26541639.html

Form 8-K TScan Therapeutics, Inc. For: May 20

Fri, 22 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260522/26541570.html

Form 8-K TScan Therapeutics, Inc. For: May 20

Fri, 22 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260522/26541570.html

Form 4 TScan Therapeutics, Inc. For: May 20 Filed by: Klencke Barbara